[go: up one dir, main page]

ATE440138T1 - Mutationen des parkin-gens, zusammensetzungen, verfahren und verwendungen - Google Patents

Mutationen des parkin-gens, zusammensetzungen, verfahren und verwendungen

Info

Publication number
ATE440138T1
ATE440138T1 AT99956079T AT99956079T ATE440138T1 AT E440138 T1 ATE440138 T1 AT E440138T1 AT 99956079 T AT99956079 T AT 99956079T AT 99956079 T AT99956079 T AT 99956079T AT E440138 T1 ATE440138 T1 AT E440138T1
Authority
AT
Austria
Prior art keywords
parkin
gene
exons
deletion
amplifying
Prior art date
Application number
AT99956079T
Other languages
English (en)
Inventor
Alexis Brice
Christophe Lucking
Nacer Abbas
Patrice Denefle
Sylvain Ricard
Sandrine Bouley
Original Assignee
Aventis Pharma Sa
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9814524A external-priority patent/FR2786199B1/fr
Priority claimed from FR9910140A external-priority patent/FR2797272B1/fr
Application filed by Aventis Pharma Sa, Inst Nat Sante Rech Med filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE440138T1 publication Critical patent/ATE440138T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
    • C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT99956079T 1998-11-19 1999-11-18 Mutationen des parkin-gens, zusammensetzungen, verfahren und verwendungen ATE440138T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9814524A FR2786199B1 (fr) 1998-11-19 1998-11-19 Mutations du gene de la parkine, compositions, methodes et utilisations
US12423999P 1999-03-12 1999-03-12
FR9910140A FR2797272B1 (fr) 1999-08-04 1999-08-04 Nouvelles mutations du gene de la parkine, compositions, methodes et utilisations
PCT/FR1999/002833 WO2000031253A2 (fr) 1998-11-19 1999-11-18 Mutations du gene de la parkine, compositions, methodes et utilisations

Publications (1)

Publication Number Publication Date
ATE440138T1 true ATE440138T1 (de) 2009-09-15

Family

ID=27253486

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99956079T ATE440138T1 (de) 1998-11-19 1999-11-18 Mutationen des parkin-gens, zusammensetzungen, verfahren und verwendungen

Country Status (15)

Country Link
US (3) US8835618B2 (de)
EP (5) EP2305816A1 (de)
JP (1) JP5424519B2 (de)
AT (1) ATE440138T1 (de)
AU (1) AU778281B2 (de)
CA (1) CA2351567C (de)
CY (1) CY1110535T1 (de)
DE (1) DE69941300D1 (de)
DK (1) DK1131424T3 (de)
ES (1) ES2330281T3 (de)
IL (3) IL142755A0 (de)
NO (5) NO330896B1 (de)
NZ (1) NZ512313A (de)
PT (1) PT1131424E (de)
WO (1) WO2000031253A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1081225A1 (de) * 1999-08-30 2001-03-07 Biofrontera Pharmaceuticals GmbH Transgenes Tiermodel für neurodegenerative Erkrankungen
US20040248092A1 (en) * 2000-05-26 2004-12-09 Vance Jeffrey M Methods of screening for parkinsons's disease
FR2845245A1 (fr) * 2002-10-07 2004-04-09 Aventis Pharma Sa Modele animal de la maladie de parkinson
US7790390B2 (en) 2004-10-27 2010-09-07 Duke University Methods for identifying an individual at increased risk of developing coronary artery disease
US7807465B2 (en) 2004-10-27 2010-10-05 Duke University Methods for identifying an individual at increased risk of developing coronary artery disease
CN110295147A (zh) * 2019-07-22 2019-10-01 新乡医学院 一种食管癌细胞系中功能基因敲除后增殖表型的快速鉴定方法及其应用
AU2021273979A1 (en) * 2020-05-21 2023-01-05 Nysnobio Gt Neurology, Llc Gene therapy delivery of Parkin mutants having increased activity to treat Parkinson's Disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817478A (en) * 1993-10-05 1998-10-06 Asahi Glass Company Ltd. Multicloning vector, expression vector and production of foreign proteins by using the expression vector
ES2168472T3 (es) 1995-06-06 2002-06-16 Beth Israel Hospital Procedimiento y aparato para ensayo diagnostico de adn.
ATE315645T1 (de) * 1998-02-09 2006-02-15 Boehringer Ingelheim Int Dns oder gene, die an der parkinsonschen krankheit beteiligt sind
CA2872581C (fr) * 1998-11-19 2018-04-10 Aventis Pharma S.A. Mutations du gene de la parkine, compositions, methodes et utilisations

Also Published As

Publication number Publication date
CA2351567A1 (fr) 2000-06-02
AU1276900A (en) 2000-06-13
NO333906B1 (no) 2013-10-14
EP1131424B1 (de) 2009-08-19
NO333907B1 (no) 2013-10-14
EP2128257A3 (de) 2010-03-03
US20150074836A1 (en) 2015-03-12
NO20012342L (no) 2001-07-18
US8835618B2 (en) 2014-09-16
WO2000031253A2 (fr) 2000-06-02
US9540693B2 (en) 2017-01-10
JP5424519B2 (ja) 2014-02-26
JP2002536961A (ja) 2002-11-05
NO330896B1 (no) 2011-08-08
IL187652A (en) 2010-02-17
NO20110580L (no) 2001-07-18
NO20110578L (no) 2001-07-18
WO2000031253A3 (fr) 2000-09-28
US20170183736A1 (en) 2017-06-29
CY1110535T1 (el) 2015-04-29
NO20110582L (no) 2001-07-18
EP2305816A1 (de) 2011-04-06
IL142755A (en) 2009-08-03
IL142755A0 (en) 2002-03-10
EP1131424A2 (de) 2001-09-12
PT1131424E (pt) 2009-10-23
NO332174B1 (no) 2012-07-16
NO20110577L (no) 2001-07-18
EP2345722A1 (de) 2011-07-20
DE69941300D1 (de) 2009-10-01
NZ512313A (en) 2003-12-19
US20120064598A1 (en) 2012-03-15
AU778281B2 (en) 2004-11-25
CA2351567C (fr) 2016-01-12
ES2330281T3 (es) 2009-12-07
EP2128257A2 (de) 2009-12-02
DK1131424T3 (da) 2009-11-23
NO332173B1 (no) 2012-07-16
NO20012342D0 (no) 2001-05-11
EP2311954A1 (de) 2011-04-20

Similar Documents

Publication Publication Date Title
CY1110535T1 (el) Μεταλλαξεις του γονιδιου της παρκινης, συνθεσεις, μεθοδοι και χρησεις
Manchenko Handbook of detection of enzymes on electrophoretic gels
Ying et al. Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome
GB2375539A (en) Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human adult liver
ATE310819T1 (de) Säugetieren apoptosis inhibitorprotein genfamilie,primers, probes und verfahren zur nachweis
Curchoe et al. Promoter-specific expression of the imprinted IGF2 gene in cattle (Bos taurus)
ATE535618T1 (de) Spezifisches verfahren zum nachweis von prostatakrebs auf grundlage des pca3-gens sowie kits dafür
JP2002521065A5 (de)
EP0274482A4 (de) Zubereitungen und verfahren für klone, die assoziierte dna-sequenzen mit mehrfacharzneimittelresistenz in menschlichen zellen enthalten.
Cao et al. MMP‐1 promoter gene polymorphism and susceptibility to chronic periodontitis in a Chinese population
Lee et al. Analysis of lung tumorigenesis in chimeric mice indicates the Pulmonary adenoma resistance 2 (Par2) locus to operate in the tumor-initiation stage in a cell-autonomous manner: detection of polymorphisms in the Polı gene as a candidate for Par2
Su et al. Two novel mutations in the gene encoding thyroxine‐binding globulin (TBG) as a cause of complete TBG deficiency in Taiwan
ATE373095T1 (de) Mutierte muskelspezifische enhancer
ATE308615T1 (de) T-bet zusammensetzungen und deren vervendungsmethoden
Manning et al. Identification of the mutation in the alkaptonuria mouse model
ATE315104T1 (de) Glaukom diagnose und behandlung
CN101240325A (zh) 一种检测遗传基因修复能力的试剂盒
EP1446485A4 (de) Diagnoseverfahren für krebs, das durch den nachweis der deletion des g-csf-exons 3 gekennzeichnet ist
DE60038029D1 (de) Methoden und reagenzien zur in situ amplifizierung
WO2002086113A3 (en) Enzyme and snp marker for disease
Silverton CRIME AND THE SCHIZOPHRENIA SPECTRUM: A STUDY OF TWO DANISH COHORTS.
Henry Differentiation of allozyme loci to distinguish between two species of Eisenia
Christensen et al. Characterization of transgenic mice with the expression of phenylalanine hydroxylase and GTP cyclohydrolase I in the skin
Friedberg et al. Calculation and verification of the ages of retroprocessed pseudogenes
Edwards et al. A non-methylated CpG-rich island associated with the human muscle-specific carbonic anhydrase III gene

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1131424

Country of ref document: EP